Skip to content
Screener

Syndax Pharmaceuticals SNDX Prepaid & Other Current

Prepaid & Other Current at other companies

Biogen logo
BiogenBIIB
$1.24B+45.5%
Incyte logo
IncyteINCY
$253.09M-14.4%
SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.SLS
$4.06M+0.3%
Kura Oncology logo
Kura OncologyKURA
$32.77M+89.8%
AbbVie logo
AbbVieABBV
$150M-97.3%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$22.32M+130%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.82B+68.8%
Enterprise value$2.04B+56.8%
P/S8.4×-5.4×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-197154
Line itemMarch 31, 2026December 31, 2025
Short-term deposits9,17519,616
Other receivables, net2676,404
Collaboration receivable, net20,50723,745
Prepaid expenses and other current assets16,10013,496
Total current assets471,177528,081
Property and equipment, net177181
Right-of-use asset, net1,2121,342
Restricted cash102102

Item 1: Financial Statements

FAQ

What is Syndax Pharmaceuticals's prepaid & other current?
Syndax Pharmaceuticals (SNDX) reported prepaid & other current of $16.1M in Q1 2026.
How has Syndax Pharmaceuticals's prepaid & other current changed year-over-year?
Syndax Pharmaceuticals's prepaid & other current increased by 90.3% year-over-year, from $8.46M to $16.1M.
What is the long-term trend for Syndax Pharmaceuticals's prepaid & other current?
Over 5 years (2020 to 2025), Syndax Pharmaceuticals's prepaid & other current has grown at a 18.9% compound annual growth rate (CAGR), from $5.68M to $13.5M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.

Ask your AI about Syndax Pharmaceuticals's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude